Zafgen rolls out positive PhIIa results for obesity drug; Mass General, Broad Institute and Amgen partner on bowel disease;

@FierceBiotech: Sanofi launches a new antibiotics effort, teams with Fraunhofer. More | Follow @FierceBiotech

@JohnCFierce: Interesting to see Chelsea Therapeautics win the solid backing of the adcomm. Now back to the FDA, where the weather has been much chillier. Odds on OK? | Follow @JohnCFierce

@DamianFierce: Regeneron, Bayer reach for the old Eylea magic with combo AMD deal. Yesterday's story | Follow @DamianFierce

@EmilyMFierce: Omnibus bill would restore $1B in funding to NIH. Story from FierceBiotech Research | Follow @EmilyMFierce

> Zafgen revealed initial results from its Phase IIa study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome (PWS), a severe form of genetic obesity. The results showed improvements in body weight, hunger-related behaviors, and body composition. Study subjects also lost body fat and preserved lean body mass following four weeks of treatment. Release

> Massachusetts General Hospital and the Broad Institute are partnering up with Amgen ($AMGN) to find new therapeutic targets and develop novel therapies for inflammatory bowel disease. Release

Medical Device News

@FierceMedDev: Covidien's ventilator recall gets hit with FDA's 'most serious' Class I label. More | Follow @FierceMedDev

@MarkHFierce: The latest weekly edition of FierceDiagnostics is all ready for you, now with added biomarker coverage. Check it out. Issue | Follow @MarkHFierce

@MichaelGFierce: Roche's delivery method 'shuttles' Alzheimer's drugs past blood-brain barrier. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Qiagen and Exosome inked a Dx development deal to create cancer biomarkers. Yesterday's story | Follow @EmilyWFierce

> Struggling Sequenom's Mayo Clinic deal expands the reach of its prenatal Dx. Story

> Medtronic and Edwards take heart valve rivalry to hospital admins. Report

> Omnibus bill would restore FDA user fees; AdvaMed, MDMA applaud. News

Pharma News

@FiercePharma: Novo Nordisk eyes IPO for its IT subsidiary, taps new CFO to lead review. Story | Follow @FiercePharma

@TracyStaton: Best-read FiercePharma Tuesday: Merck CEO: We'll decide on animal health, consumer biz by year-end. Story | Follow @TracyStaton

@EricPFierce: McKesson fails to get EU drug distributor Celesio. Some see the miss as a shame for both. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Drug buyers sue Novo Nordisk over 'wrongful' delays to diabetes generic. Yesterday's story | Follow @CarlyHFierce

> Merck recall depletes supplies of new cholesterol drug. Item

> Lilly CEO Lechleiter predicts big things after its 'most financially challenging year.' Piece

> Glaxo CFO: China sales on the rebound after that big hit from the bribery scandal. Story

Drug Delivery News

> Roche's delivery method 'shuttles' Alzheimer's drugs past the blood-brain barrier. Story

> 'On-off' switch in disguised nanoparticles shows delivery potential. Story

> Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. Story

> Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. Item

> Elixir places first DESolve drug-eluting stent in patient. Article

> Amid RNAi buzz, Arcturus touts positive preclinical results. More

Diagnostics News

> J&J will link with a Seattle Dx outfit on a biomarker discovery program. Story

> Ovarian cancer biomarker could predict treatment response and help prevent metastasis. Story

> Microlin Bio files for a $25M IPO to advance cancer Dx and Rx treatments. Story

> Dutch research hospital teams with Probiodrug to assess Alzheimer's biomarker assays. Story

> Dako joins with Merck to concoct cancer treatment companion Dx tests. Article

> Quest seals 3 new Dx development deals. Item

Suggested Articles

Novartis is picking up Vedere Bio and its preclinical gene therapies for $150 million upfront, with the promise of another $130 million.

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.